查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1837193

病毒惰性市场按产品、方法、应用和最终用户划分－2025-2032年全球预测

Viral Inactivation Market by Product, Method, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，病毒惰性市场规模将达到 34.3 亿美元，复合年增长率为 15.04%。

关键市场统计数据
基准年 2024 11.1亿美元
预计年份：2025年 12.8亿美元
预测年份 2032 34.3亿美元
复合年增长率 (%) 15.04%

揭示病毒惰性的策略和科学背景，重点是阐述跨部门驱动因素以及为何综合解决方案对营运韧性至关重要

病毒惰性领域已发展成为一个技术高度复杂、跨学科的领域，它融合了法律规范和营运要求，旨在保护公众健康和保障商业连续性。本导言探讨了影响现代决策的关键主题：化学、物理和热力方法之间的技术融合；各类产品监管力度的加强；以及从研发到部署的全程验证的日益重视。阐明这些背景有助于相关人员更好地理解，耗材和设备的创新是如何受到空气、水、食品和製药系统实际需求的驱动。

此外，本导言重点阐述了为何综合方法正日益受到支持。对于希望在各种环境条件下获得可重复结果的机构而言，将消毒剂和化学试剂套件等耗材与专用设备相结合的多学科策略至关重要。同时，法规遵循和操作人员安全的考量正推动产品设计朝向降低毒性、增强可追溯性和简化通讯协定发展。因此，本导言将病毒惰性定位为一项策略能力，它不仅关乎实验室层面，更关乎整个供应链和关键服务的韧性。

新兴技术、监管重点和业务需求如何融合，从而重塑通讯协定并促进病毒惰性方法的整合

病毒惰性领域正经历一场变革，这主要得益于技术进步和相关人员不断变化的需求。新型设备和自动化技术提高了处理效率和一致性，而化学配方和紫外线光源的创新则改善了频谱覆盖范围和材料相容性。因此，从业人员正逐渐从依赖单一方法转向结合化学、热学和物理方法的混合通讯协定，以实现对各种基质的高效灭活。

监管和社会压力也在改变产品的采用模式。除了遵守既定标准外，企业现在还面临永续性、员工安全和可验证可追溯性的要求。这些趋势促使製造商设计出能够最大限度减少有害产品差异、降低能源消耗并提供检验的监管链数据的产品。同时，数位化正在增强监控和检验。内建感测器和远距离诊断能够实现持续的效能评估和预测性维护，从而减少停机时间，并在更长的服务週期内保持产品的有效性。总而言之，这些转变正在开启一个新时代，在这个时代，多学科产品系列和以证据为导向的部署策略将成为实现竞争优势和赢得公众信任的基础。

评估美国近期关税调整如何重塑病毒惰性价值链的筹资策略、供应链韧性和供应商关係。

美国2025年实施的关税和贸易政策调整对病毒惰性生态系统的供应链、筹资策略和供应商关係产生了连锁反应。对于依赖进口组件（例如专用灯具、辐射源和某些化学前驱物）的机构而言，进口成本的增加促使他们更加关注供应链的韧性和总到岸成本。因此，采购团队和技术负责人正在优先考虑供应商多元化、尽可能在地采购以及长期合约安排，以降低政策波动带来的风险。

此外，这些贸易动态正在加速製造和组装本地化倡议。企业正在评估关键设备和耗材的近岸外包方案，以缩短前置作业时间并加强品管。同时，研发计画也进行了调整，更加重视替代化学方法和模组化设备架构，以便在不影响功能性能的前提下替换受影响的组件。最后，行业相关人员正在加强与监管机构和贸易当局的沟通，以明确分类、关税待遇和合规要求，他们认识到，积极主动的政策对话可以减少营运不确定性，并维持关键病毒惰性能力的持续性。

从产品、方法、应用和最终用户等维度进行详细的細項分析，以指南病毒惰性的选择、检验和部署策略。

了解这种细分对于制定病毒惰性产品选择和部署策略至关重要。耗材包括化学试剂套件、消毒剂和紫外线灯，这些产品均针对常规应用或更换而配製或包装。设备包括过滤系统、辐照平台和灭菌机，它们构成耐用的基础设施，并需要不同的验证和维护方案。这种细分会影响采购时机、操作人员培训需求以及生命週期管理实务。

从方法来看，该领域可分为化学处理、热处理和物理处理三大类。化学处理方法包括使用二氧化氯、环氧乙烷和过氧化氢等试剂，每种试剂都因其特定的有效性、材料相容性和可加工性而被选中。热处理方法分为干热和湿热两种，可提供适用于不同基材的穿透深度和衝击特性。物理处理方法包括电子束、伽马射线和紫外线技术。紫外线处理方法又包括低压汞灯和脉衝氙灯等子类型，这些子类型在频谱输出、能量效率以及对不同表面和气流的适用性方面各不相同。

空气净化包括暖通空调系统和可携式净化器，旨在降低空气中的病毒量。食品加工涵盖饮料、乳製品和肉类加工，每种加工方式都有其独特的卫生处理流程和监管限制。原料药生产涵盖活性生技药品和疫苗的生产，其中无菌性和无菌保证至关重要。水处理涵盖饮用水和污水处理，需要在有效控制副产物产生的同时，大幅降低病毒含量。最终使用者定义了操作要求和验证的严格程度。生技公司（分为诊断和治疗开发公司）要求可追溯性和通讯协定可重复性。食品和饮料加工商（涵盖饮料、乳製品和肉类加工厂）优先考虑产量和残留安全性。诊所和医院等医疗机构需要快速、安全且检验的惰性。实验室，包括临床和研究环境，需要灵活的方法来支援各种检测和生物安全等级。

比较美洲、欧洲、中东和非洲以及亚太地区的区域动态和监管差异，这些差异会影响技术采纳和采购选择。

区域观点影响病毒惰性的优先事项、监管环境和技术应用模式。在美洲，优先考虑营运扩充性、与现有基础设施的整合以及遵守严格的公共卫生和职业安全标准，往往促使企业投资于能够实现高通量和可预测检验结果的系统。因此，相关人员倾向于选择兼具成熟有效性、高效运作和清晰合规路径的解决方案。

监管协调和永续性要求是欧洲、中东和非洲的关键驱动因素。在这些市场，政策制定者和机构投资者对环保化学品、节能设备和生命週期透明度表现出浓厚的兴趣。该地区的许多组织正在采用能够减少危险废弃物并促进循环经济实践的技术，同时，采购决策也受到多方相关人员的审查。

在亚太地区，快速的工业扩张、多样化的气候条件以及监管成熟度的差异，既带来了挑战，也带来了机会。市场采用的解决方案强调成本效益、对当地营运条件的适应性以及能够在製造业和市政基础设施中大规模部署的能力。区域製造商和整合商正透过创新来满足对模组化系统和本地化支援网络的需求，而全球供应商则在建立伙伴关係和服务网络，以确保在不同司法管辖区都能应对力并符合相关规定。

整合的产品系列、策略伙伴关係和服务模式如何塑造竞争差异化，从而加速产品普及化并确保合规性？

病毒惰性领域的企业正透过技术深度、监管合规性和以服务为导向的产品组合脱颖而出。领先企业正投资于将耗材与相容设备结合的产品系列，从而提供捆绑式解决方案，简化终端用户的采购和检验。此外，随着各组织寻求提供能够减少采用障碍的承包解决方案，组件製造商、设备製造商和系统整合商之间的策略伙伴关係也变得越来越普遍。

研发管线专注于提升安全性、扩大对不同病毒家族的疗效以及增强易用性。这促使企业加强与学术和临床研究中心的合作，以进行独立的绩效检验和真实世界检验。同时，各公司也不断完善市场推广策略，提供延长保固期、远端监控服务和培训项目，以确保正确安装和持续有效运作。合规方面的专业知识也是企业脱颖而出的关键。能够驾驭复杂且竞争激烈的法规环境并提供完善检验文件的公司，更受製药企业和医疗机构等高风险终端用户的青睐。

产业领导者可采取切实可行的步骤，加强验证实务、供应链韧性、监管参与和员工能力，以维持病毒惰性计画。

产业领导者应优先采用以证据主导的综合方法来维持产品的有效性、安全性和供应的连续性。首先，投资于模组化解决方案架构，以便在不改造整个系统的情况下更换组件，从而保持营运灵活性并简化风险缓解措施。其次，建立跨职能验证通讯协定，将实验室有效性测试与现场性能监测相结合，以确保方法在实际应用条件下的稳健性。这样做有助于企业降低变异性并增强相关人员的信心。

此外，企业必须将供应链韧性提升至策略要务。关键零件供应商应多元化，尽可能在本地进行生产和组装，并纳入合约保障措施以应对关税和贸易风险。同时，应优先考虑能够最大限度减少有害副产品和能源消耗的产品设计，以符合日益严格的法规和永续性预期。与监管机构合作并参与标准制定流程也有助于缩短核准时间，并明确遵守途径。最后，企业应投资于培训模组、数位化支援工具和能力评估，以提升员工能力，确保营运的稳定性和安全性，并在员工流动率不断上升的情况下维护组织知识。

采用透明的混合方法研究途径，整合一手访谈、二手文献综述和检验通讯协定，以确保获得可靠且可操作的见解。

本报告的调查方法整合了多方面的证据，旨在提供可靠、可追溯的洞见，同时保持方法论的透明度。主要质性研究包括对临床、工业和实验室环境中的最终使用者进行结构化访谈，以及咨询病毒学、材料科学和法规事务领域的专家。这些访谈旨在了解操作限制、验证实务和采购优先事项，并在保密条件下进行，以获得坦诚、务实的观点。

二级研究系统地查阅了同行评审文献、技术标准、监管指导文件和供应商技术规范，以确定技术特性和适用性的基础。实验室性能数据与独立的检验研究进行交叉比对，以检验功效声明并了解方法的局限性。数据综合采用三角测量技术来协调不同资讯来源之间的差异，研究结果经过内部同侪审查和品质检查。伦理考量，包括访谈资料的匿名化和潜在利益衝突的揭露，是确保分析可靠性和可重复性的方法论的重要组成部分。

检验综合和策略重点，着重于可重复验证、供应链适应性和永续设计

总之，病毒惰性已发展成为一个多学科交叉领域，技术创新、监管要求和实际操作情况相互交织，共同决定最终的成功。整合耗材和设备、采用混合方法并纳入持续监测的整合策略正日益被公认为最佳实践。随着各组织机构应对不断变化的政策环境和供应链压力，其韧性将取决于能否在维持严格的安全性和有效性标准的同时，灵活调整采购、检验和部署模式。

展望未来，相关人员，将更有能力把技术进步转化为可靠的营运绩效。透过专注于可重复检验、供应链适应性和永续设计原则，实验室可以确保其病毒惰性策略不仅满足当前的营运需求，还能支持长期的公共卫生和商业连续性目标。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 疫情应对策略推动了UV-C LED消毒系统在医疗机构和公共交通枢纽的快速应用。
  • 向养老院和医院引入自动化机器人表面消毒解决方案，以高效消除病毒
  • 消费者清洁产品市场对环保型和可生物降解的化学杀病毒配方的需求日益增长
  • 照护现场病毒惰性设备在临床环境中的出现，旨在最大限度地降低交叉感染风险。
  • 关键市场病毒功效测试标准的监管协调统一将缩短产品核可时间。
  • 增加对奈米技术的投资，为公共场所高频接触表面提供抗病毒涂层，以减少感染传播。
  • 开发一种基于物联网的监测平台，用于即时追踪工业环境中的病毒惰性过程
  • 采用动态疗法和化学消毒剂结合的通讯协定来增强病毒抑制效果。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 病毒惰性产品市场

  • 消耗品
    • 化学试剂套件
    • 消毒剂
    • 紫外线灯
  • 装置
    • 过滤设备
    • 照射装置
    • 消毒器

9. 依方法分類的病毒惰性市场

  • 化学处理
    • 二氧化氯
    • 环氧乙烷
    • 过氧化氢
  • 热处理
    • 干热
    • 湿热
  • 物理处理
    • 电子束
    • 伽玛射线
    • 紫外线
      • 低压汞
      • 脉衝氙气

第十章 病毒惰性市场（依应用领域划分）

  • 空气净化
    • 暖通空调系统
    • 可携式水质净化器
  • 食品加工
    • 饮料加工
    • 乳製品加工
    • 肉类加工
  • 製药生产
    • API生产
    • 生物製药生产
    • 疫苗生产
  • 水处理
    • 饮用水处理
    • 污水处理

第十一章 病毒惰性市场（依最终用户划分）

  • 生技公司
    • 诊断开发人员
    • 治疗药物研发人员
  • 食品和饮料加工商
    • 饮料厂
    • 乳品厂
    • 肉类加工厂
  • 医疗机构
    • 诊所
    • 医院
  • 研究所
    • 临床实验室
    • 实验室

第十二章 病毒惰性市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 病毒惰性市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国病毒惰性市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Ecolab Inc.
    • STERIS Corporation
    • 3M Company
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Sartorius AG
    • Danaher Corporation
    • Lonza Group AG
    • Repligen Corporation
    • Novasep SAS
Product Code: MRR-034B5003039F

The Viral Inactivation Market is projected to grow by USD 3.43 billion at a CAGR of 15.04% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.11 billion
Estimated Year [2025] USD 1.28 billion
Forecast Year [2032] USD 3.43 billion
CAGR (%) 15.04%

Establishing the strategic and scientific context for viral inactivation to illuminate cross-sector drivers and why integrated solutions are pivotal for operational resilience

The viral inactivation domain has evolved into a technically sophisticated and cross-sectoral discipline, where science, regulatory frameworks, and operational requirements intersect to protect public health and commercial continuity. This introduction frames the critical themes that shape contemporary decision-making: technological convergence among chemical, physical, and thermal methods; heightened regulatory scrutiny across product classes; and a stronger emphasis on end-to-end validation from R&D through deployment. By establishing this context, stakeholders can better appreciate how innovations in consumables and equipment are being driven by practical needs in air, water, food, and pharmaceutical systems.

Moreover, the introduction underscores why integrated approaches are gaining favor. As organizations seek to deliver reproducible outcomes under varied environmental conditions, multidisciplinary strategies that pair consumables such as disinfectant solutions and chemical kits with specialized equipment become essential. At the same time, regulatory compliance and operator safety considerations are steering product design toward reduced toxicity, enhanced traceability, and simplified protocols. Therefore, this opening section situates viral inactivation not merely as a laboratory concern but as a strategic capability that underpins resilience across supply chains and critical services.

How emerging technologies, regulatory priorities, and operational demands are converging to reshape protocols and fuel integrated viral inactivation approaches

The landscape for viral inactivation is undergoing transformative shifts propelled by technological advances and evolving stakeholder expectations. New instrumentation and automation have increased throughput and consistency, while innovations in chemical formulations and UV sources have improved spectrum coverage and material compatibility. Consequently, practitioners are progressively moving away from single-method reliance toward hybrid protocols that combine chemical, thermal, and physical modalities to achieve robust inactivation across diverse matrices.

Regulatory and societal pressures are also reshaping adoption patterns. In addition to compliance with established standards, organizations now face demands for sustainability, worker safety, and demonstrable traceability. These dynamics are prompting manufacturers to design products that minimize hazardous byproducts, reduce energy intensity, and offer verifiable chain-of-custody data. Simultaneously, digitalization is enhancing monitoring and validation; embedded sensors and remote diagnostics allow continuous performance assessment and enable predictive maintenance, which reduces downtime and preserves efficacy over extended service cycles. Taken together, these shifts are driving a new era in which multidisciplinary product portfolios and evidence-centered deployment strategies are the basis for competitive differentiation and public confidence.

Assessing how recent United States tariff adjustments have reshaped procurement strategies, supply chain resilience, and supplier relationships across viral inactivation value chains

The introduction of tariffs and trade policy adjustments in the United States during 2025 has created ripple effects across supply chains, procurement strategies, and vendor relationships that touch the viral inactivation ecosystem. For organizations that rely on imported components such as specialized lamps, radiation sources, or certain chemical precursors, increased import costs have elevated attention on supply chain resilience and total landed cost. As a result, procurement teams and technical leaders have prioritized supplier diversification, local sourcing where feasible, and longer-term contractual arrangements to mitigate exposure to policy fluctuations.

Moreover, these trade dynamics have accelerated localization initiatives in manufacturing and assembly. Firms are evaluating nearshoring options for critical equipment and consumables to reduce lead times and strengthen quality control. In parallel, research and development planning has adapted by emphasizing alternative chemistries and modular equipment architectures that permit substitution of impacted components without compromising functional performance. Finally, industry stakeholders have intensified engagement with regulatory and trade authorities to clarify classification, duty treatment, and compliance requirements, recognizing that proactive policy dialogue can reduce operational uncertainty and maintain continuity of essential viral inactivation capabilities.

Detailed segmentation analysis across product, method, application, and end-user dimensions to guide selection, validation, and deployment strategies in viral inactivation

Understanding segmentation is essential to navigating product selection and deployment strategies in viral inactivation. When the market is examined by product, there is a clear bifurcation between consumables and equipment: consumables encompass chemical kits, disinfectant solutions, and UV lamps that are formulated or packaged for routine application and replacement, while equipment covers filtration systems, irradiation platforms, and sterilization machinery that provide durable infrastructure and require different validation and maintenance regimes. This division informs purchasing cadence, operational training needs, and lifecycle management practices.

In terms of method, the domain is shaped by chemical treatment, heat treatment, and physical treatment categories. Chemical approaches include agents such as chlorine dioxide, ethylene oxide, and hydrogen peroxide, each chosen for specific efficacy, material compatibility, and throughput considerations. Heat-based methods split into dry heat and moist heat options, delivering differing penetrative and material impact profiles suitable for varying substrates. Physical modalities involve electron beam, gamma radiation, and ultraviolet technologies; within ultraviolet approaches there are subtypes such as low pressure mercury and pulsed xenon sources, which differ in spectral output, energy efficiency, and applicability across surfaces and air volumes.

Application-driven segmentation further clarifies deployment contexts: air purification spans HVAC systems and portable purifiers designed to reduce airborne viral load; food processing encompasses beverage processing, dairy processing, and meat processing with unique sanitation cycles and regulatory constraints; pharmaceutical manufacturing includes active pharmaceutical ingredient production, biologics production, and vaccine production where sterility and aseptic assurance are paramount; water treatment addresses drinking water and wastewater treatment operations that require robust viral reduction while managing byproduct formation. Finally, end users define operational requirements and validation rigor: biotechnology firms-split between diagnostic developers and therapeutics developers-demand traceability and protocol reproducibility; food and beverage processors-across beverage, dairy, and meat plants-prioritize throughput and residual safety; healthcare facilities such as clinics and hospitals need rapid, safe, and verifiable inactivation; and laboratories, including clinical and research settings, require flexible methods that support a range of assays and containment levels.

Comparative regional dynamics and regulatory nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence technology adoption and procurement choices

Regional perspectives shape priorities, regulatory requirements, and technology adoption patterns across the viral inactivation landscape. In the Americas, emphasis tends to center on operational scalability, integration with existing infrastructure, and adherence to stringent public health and occupational safety standards; investments frequently target systems that enable high throughput and predictable validation outcomes. Consequently, stakeholders favor solutions that combine proven efficacy with operational efficiency and clear compliance pathways.

In Europe, Middle East & Africa, regulatory harmonization efforts and sustainability mandates are influential drivers. Across these markets, policymakers and institutional purchasers exhibit strong interest in environmentally responsible chemistries, energy-efficient equipment, and lifecycle transparency. Many organizations in this region are adopting technologies that reduce hazardous waste and enable circular economy practices, while procurement decisions are informed by multi-stakeholder scrutiny.

In the Asia-Pacific region, rapid industrial expansion, diverse climatic conditions, and varying regulatory maturity create both challenges and opportunities. Adoption patterns emphasize cost-effectiveness, adaptability to local operational contexts, and solutions that can be deployed at scale across manufacturing and municipal infrastructures. Regional manufacturers and integrators are innovating to meet demand for modular systems and localized support networks, while global suppliers are establishing partnerships and service footprints to ensure responsiveness and compliance across diverse jurisdictions.

How competitive differentiation is being shaped by integrated product portfolios, strategic partnerships, and service models that accelerate adoption and ensure regulatory compliance

Companies operating in the viral inactivation arena are differentiating through a mix of technological depth, regulatory alignment, and service-oriented offerings. Leaders are investing in product portfolios that blend consumables with compatible equipment, thereby enabling bundled solutions that simplify procurement and validation for end users. In addition, strategic partnerships between ingredient formulators, equipment manufacturers, and systems integrators are becoming more common as organizations look to offer turnkey solutions that reduce adoption friction.

Research and development pipelines are focused on improving safety profiles, expanding efficacy across viral families, and enhancing ease of use. This has prompted increased collaboration with academic and clinical research centers for independent performance verification and real-world validation. Meanwhile, companies are refining their go-to-market strategies by offering extended warranties, remote monitoring services, and training programs to ensure proper installation and sustained performance. Competitive differentiation also arises from compliance expertise; firms that can navigate complex regulatory environments and provide documented validation packages gain preferential consideration among high-stakes end users such as pharmaceutical manufacturers and healthcare institutions.

Actionable steps for industry leaders to strengthen validation practices, supply chain resilience, regulatory engagement, and workforce capability to sustain viral inactivation programs

Industry leaders should prioritize an integrated, evidence-driven approach to maintain efficacy, safety, and supply continuity. First, invest in modular solution architectures that allow substitution of components without requalifying entire systems, which preserves operational flexibility and simplifies risk mitigation. Second, establish cross-functional validation protocols that combine laboratory efficacy testing with field performance monitoring to ensure method resilience across real-world conditions. By doing so, organizations can reduce variability and strengthen stakeholder confidence.

Furthermore, supply chain resilience must be elevated to a strategic imperative. Diversify suppliers for critical components, pursue localized manufacturing or assembly where feasible, and include contractual safeguards that address tariff and trade risk. In parallel, prioritize product designs that minimize hazardous byproducts and energy consumption to align with tightening regulatory and sustainability expectations. Collaboration with regulatory bodies and participation in standards development processes will also pay dividends by reducing approval timelines and clarifying compliance pathways. Finally, invest in workforce capability building-training modules, digital support tools, and competency assessments-to ensure consistent, safe operation and to preserve institutional knowledge amid workforce turnover.

A transparent mixed-methods research approach integrating primary interviews, secondary literature synthesis, and validation protocols to ensure credible and actionable insights

The research methodology underpinning this report synthesizes multiple evidence streams to provide robust, traceable insights while maintaining methodological transparency. Primary qualitative engagement included structured interviews with end users across clinical, industrial, and laboratory settings, along with consultations with subject-matter experts in virology, materials science, and regulatory affairs. These interviews were designed to capture operational constraints, validation practices, and procurement priorities, and were conducted under confidentiality to elicit candid, practical perspectives.

Secondary research encompassed a systematic review of peer-reviewed literature, technical standards, regulatory guidance documents, and supplier technical specifications to establish an evidence base for technology characteristics and application fit. Laboratory performance data and independent validation studies were cross-referenced to verify efficacy claims and to understand method limitations. Data synthesis applied triangulation techniques to reconcile differences across sources, and findings were subject to internal peer review and quality checks. Ethical considerations, including anonymization of interview data and disclosure of potential conflicts of interest, were integral to the methodology to ensure credibility and reproducibility of the analysis.

Synthesis of evidence and strategic priorities that emphasize reproducible validation, supply chain adaptability, and sustainable design for enduring operational effectiveness

In conclusion, viral inactivation has matured into a multidisciplinary field where technical innovation, regulatory requirements, and operational realities coalesce to determine successful outcomes. Integrated strategies that combine consumables and equipment, leverage hybrid methodologies, and incorporate continuous monitoring are increasingly recognized as best practice. As organizations contend with evolving policy environments and supply chain pressures, resilience will hinge on the ability to adapt procurement, validation, and deployment models while maintaining rigorous safety and efficacy standards.

Looking ahead, stakeholders who prioritize evidence-backed product selection, proactive engagement with regulatory bodies, and investments in workforce capability will be best positioned to translate technological advances into dependable operational performance. By focusing on reproducible validation, supply chain adaptability, and sustainable design principles, institutions can ensure that viral inactivation strategies not only meet immediate operational needs but also support long-term public health and commercial continuity objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of UV-C LED disinfection systems in healthcare and public transportation hubs driven by pandemic preparedness strategies
  • 5.2. Integration of automated robotic surface disinfection solutions in nursing homes and hospitals for efficient viral elimination
  • 5.3. Rising demand for green and biodegradable chemical virucidal formulations in consumer cleaning products markets
  • 5.4. Emergence of point of care viral inactivation devices in clinical settings to minimize cross contamination risks
  • 5.5. Regulatory alignment on viral efficacy testing standards across key markets improving product approval timelines
  • 5.6. Increased investment in nanotechnology enabled antiviral coatings for high touch public surfaces to reduce transmission
  • 5.7. Development of IoT enabled monitoring platforms for real time tracking of viral inactivation processes in industrial settings
  • 5.8. Adoption of combined photodynamic therapy and chemical disinfectant protocols to enhance viral suppression efficacy

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Viral Inactivation Market, by Product

  • 8.1. Consumables
    • 8.1.1. Chemical Kits
    • 8.1.2. Disinfectant Solutions
    • 8.1.3. Uv Lamps
  • 8.2. Equipment
    • 8.2.1. Filtration Equipment
    • 8.2.2. Irradiation Equipment
    • 8.2.3. Sterilization Equipment

9. Viral Inactivation Market, by Method

  • 9.1. Chemical Treatment
    • 9.1.1. Chlorine Dioxide
    • 9.1.2. Ethylene Oxide
    • 9.1.3. Hydrogen Peroxide
  • 9.2. Heat Treatment
    • 9.2.1. Dry Heat
    • 9.2.2. Moist Heat
  • 9.3. Physical Treatment
    • 9.3.1. Electron Beam
    • 9.3.2. Gamma Radiation
    • 9.3.3. Ultraviolet
      • 9.3.3.1. Low Pressure Mercury
      • 9.3.3.2. Pulsed Xenon

10. Viral Inactivation Market, by Application

  • 10.1. Air Purification
    • 10.1.1. Hvac Systems
    • 10.1.2. Portable Purifiers
  • 10.2. Food Processing
    • 10.2.1. Beverage Processing
    • 10.2.2. Dairy Processing
    • 10.2.3. Meat Processing
  • 10.3. Pharmaceutical Manufacturing
    • 10.3.1. API Production
    • 10.3.2. Biologics Production
    • 10.3.3. Vaccine Production
  • 10.4. Water Treatment
    • 10.4.1. Drinking Water Treatment
    • 10.4.2. Wastewater Treatment

11. Viral Inactivation Market, by End User

  • 11.1. Biotechnology Firms
    • 11.1.1. Diagnostic Developers
    • 11.1.2. Therapeutics Developers
  • 11.2. Food And Beverage Processors
    • 11.2.1. Beverage Plants
    • 11.2.2. Dairy Plants
    • 11.2.3. Meat Plants
  • 11.3. Healthcare Facilities
    • 11.3.1. Clinics
    • 11.3.2. Hospitals
  • 11.4. Laboratories
    • 11.4.1. Clinical Laboratories
    • 11.4.2. Research Laboratories

12. Viral Inactivation Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Viral Inactivation Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Viral Inactivation Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Ecolab Inc.
    • 15.3.2. STERIS Corporation
    • 15.3.3. 3M Company
    • 15.3.4. Thermo Fisher Scientific Inc.
    • 15.3.5. Merck KGaA
    • 15.3.6. Sartorius AG
    • 15.3.7. Danaher Corporation
    • 15.3.8. Lonza Group AG
    • 15.3.9. Repligen Corporation
    • 15.3.10. Novasep SAS

LIST OF FIGURES

  • FIGURE 1. GLOBAL VIRAL INACTIVATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS VIRAL INACTIVATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA VIRAL INACTIVATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. VIRAL INACTIVATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. VIRAL INACTIVATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VIRAL INACTIVATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VIRAL INACTIVATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VIRAL INACTIVATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DISINFECTANT SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DISINFECTANT SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DISINFECTANT SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DISINFECTANT SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DISINFECTANT SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DISINFECTANT SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY UV LAMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY UV LAMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY UV LAMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY UV LAMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY UV LAMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY UV LAMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FILTRATION EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FILTRATION EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FILTRATION EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FILTRATION EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FILTRATION EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FILTRATION EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY IRRADIATION EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY IRRADIATION EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY IRRADIATION EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY IRRADIATION EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY IRRADIATION EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY IRRADIATION EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY STERILIZATION EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY STERILIZATION EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY STERILIZATION EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY STERILIZATION EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY STERILIZATION EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY STERILIZATION EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHLORINE DIOXIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHLORINE DIOXIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHLORINE DIOXIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHLORINE DIOXIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHLORINE DIOXIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHLORINE DIOXIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ETHYLENE OXIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ETHYLENE OXIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ETHYLENE OXIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ETHYLENE OXIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ETHYLENE OXIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ETHYLENE OXIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HYDROGEN PEROXIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HYDROGEN PEROXIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HYDROGEN PEROXIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HYDROGEN PEROXIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HYDROGEN PEROXIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HYDROGEN PEROXIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRY HEAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRY HEAT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRY HEAT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRY HEAT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRY HEAT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRY HEAT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MOIST HEAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MOIST HEAT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MOIST HEAT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MOIST HEAT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MOIST HEAT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MOIST HEAT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ELECTRON BEAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ELECTRON BEAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ELECTRON BEAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ELECTRON BEAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ELECTRON BEAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ELECTRON BEAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY GAMMA RADIATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY GAMMA RADIATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY GAMMA RADIATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY GAMMA RADIATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY GAMMA RADIATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY GAMMA RADIATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LOW PRESSURE MERCURY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LOW PRESSURE MERCURY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LOW PRESSURE MERCURY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LOW PRESSURE MERCURY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LOW PRESSURE MERCURY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LOW PRESSURE MERCURY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PULSED XENON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PULSED XENON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PULSED XENON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PULSED XENON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PULSED XENON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PULSED XENON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HVAC SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HVAC SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HVAC SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HVAC SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HVAC SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HVAC SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PORTABLE PURIFIERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PORTABLE PURIFIERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PORTABLE PURIFIERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PORTABLE PURIFIERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PORTABLE PURIFIERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PORTABLE PURIFIERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PROCESSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PROCESSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PROCESSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PROCESSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PROCESSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PROCESSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PROCESSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PROCESSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PROCESSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY API PRODUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY API PRODUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY API PRODUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY API PRODUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY API PRODUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY API PRODUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOLOGICS PRODUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOLOGICS PRODUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOLOGICS PRODUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOLOGICS PRODUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOLOGICS PRODUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOLOGICS PRODUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY VACCINE PRODUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY VACCINE PRODUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY VACCINE PRODUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY VACCINE PRODUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY VACCINE PRODUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY VACCINE PRODUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRINKING WATER TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRINKING WATER TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRINKING WATER TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRINKING WATER TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRINKING WATER TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRINKING WATER TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WASTEWATER TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WASTEWATER TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WASTEWATER TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WASTEWATER TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WASTEWATER TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WASTEWATER TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DIAGNOSTIC DEVELOPERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DIAGNOSTIC DEVELOPERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DIAGNOSTIC DEVELOPERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DIAGNOSTIC DEVELOPERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DIAGNOSTIC DEVELOPERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DIAGNOSTIC DEVELOPERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY THERAPEUTICS DEVELOPERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY THERAPEUTICS DEVELOPERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY THERAPEUTICS DEVELOPERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY THERAPEUTICS DEVELOPERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY THERAPEUTICS DEVELOPERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY THERAPEUTICS DEVELOPERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL VIRAL INACTIVATION MARKET SI